SCL Science Q1 2026: Revenue surges 238%, operating loss narrows, debt ratio 244%

Consolidated revenue 7.66B KRW (+238% YoY), operating loss 0.65B (vs 1.35B loss), controlling net loss 0.85B (vs 1.62B)
Bio logistics (64.6%) and HIS system (25%) drive growth; medical device sales 0.85B (11.1%)
Convertible bonds 14B, borrowings 12.97B, debt ratio 244%; cash 2.66B (down from 4.17B)
Accumulated deficit 44.29B, no dividends
Key contracts: business transfers from SCL (9.5B), supply agreement with VIT LLC ($384K)
R&D expense 0.13B (2% of revenue), 34 patents registered
Stock dividend (1:3) and comprehensive share exchange completed